• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants
【2h】

Age as a Risk Factor for Stroke in Atrial Fibrillation Patients: Implications in Thromboprophylaxis in the Era of Novel Oral Anticoagulants

机译：年龄是房颤患者中风的危险因素：新型口服抗凝剂时代血栓预防的意义

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Atrial fibrillation is associated with significant morbidity and mortality. There is a strong relationship between atrial fibrillation and aging, thromboembolism, stroke, congestive heart failure and hypertension. In addition, advanced age is a powerful risk factor for stroke and thromboembolism in patients with atrial fibrillation.For many years, vitamin K antagonists were the only approved anticoagulants for the management of atrial fibrillation. Lately new anticoagulants made their appearance and large trials have already shown their superiority against vitamin K antagonists. Since the arrhythmia is encountered frequently in the elderly, it is crucial to identify the beneficial effects of the novel oral anticoagulants in this particular patient population.
机译：心房纤颤与明显的发病率和死亡率有关。心房纤颤与衰老，血栓栓塞，中风，充血性心力衰竭和高血压之间存在密切关系。此外，高龄是房颤患者中风和血栓栓塞的重要危险因素。多年来，维生素K拮抗剂是唯一被批准用于治疗房颤的抗凝剂。最近出现了新的抗凝剂，大量试验已经显示出它们对维生素K拮抗剂的优越性。由于老年人心律失常频发，因此确定新型口服抗凝剂在该特定患者人群中的有益作用至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号